Asa Abeliovich is President & CEO of Prevail Therapeutics Inc.. Currently has a direct ownership of 0 shares of PRVL, which is worth approximately $0. The most recent transaction as insider was on Jan 22, 2021, when has been sold 2,385,756 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

Asa Abeliovich Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 22 2021
SELL
Disposition due to a tender of shares in a change of control transaction
-
2,385,756 Reduced 100.0%
0 Common Stock
Dec 30 2020
SELL
Payment of exercise price or tax liability
$2,049,632 $23.02 p/Share
89,037 Reduced 3.6%
2,385,756 Common Stock
Dec 30 2020
BUY
Exercise of conversion of derivative security
$656,639 $5.22 p/Share
125,793 Added 4.84%
2,474,793 Common Stock
AA

Asa Abeliovich

President & CEO
New York, NY

Track Institutional and Insider Activities on PRVL

Follow Prevail Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRVL shares.

Notify only if

Insider Trading

Get notified when an Prevail Therapeutics Inc. insider buys or sells PRVL shares.

Notify only if

News

Receive news related to Prevail Therapeutics Inc.

Track Activities on PRVL